The Swiss group NOVARTIS is to acquire the Slovenian laboratory LEK (turnover $198 million during the first half of 2002), specialised in the manufacture of generic medicines. The amount of the operation is expected to be EUR 765 million, according to LEK's current stock exchange capitalisation.